Free shipping on all orders over $ 500

c-Met c-Met

Cat.No.  Name Information
M1766 PF-04217903 PF-04217903 (PF-4217903) is a novel ATP-competitive small molecule inhibitor of c-Met kinases with the IC50 values from 3.1 nM to142 nM.
M2080 Capmatinib (INCB28060) Capmatinib (INCB28060) is a novel inhibitor of c-MET kinase with IC50 of 0.13 nM.
M1765 Crizotinib (PF-02341066) Crizotinib (PF-02341066) is a potent, orally bioavailable, ATP-competitive small-molecule inhibitor of c-Met kinase and ALK (anaplastic lymphoma kinase) with IC50 values to be 4 and 25 nM for C-Met and ALK resepectively.
M1757 XL-184 XL184 is a small molecule inhibits multiple receptor tyrosine kinases, specifically MET and VEGFR2 with IC50 values of 0.035 and 1.8 nM for VEGFR2 and Met respectively.
M3767 Merestinib Merestinib (LY2801653) is a potent, orally bioavailable c-Met inhibitor (Ki=2 nM) with anti-tumor activities. Merestinib (LY2801653) also has potent activity against MST1R (IC50=11 nM), FLT3 (IC50=7 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TEK (IC50=63 nM), ROS1, DDR1/2 (IC50=0.1/7 nM) and MKNK1/2 (IC50=7 nM).
M3515 MK-2461 MK-2461 is a potent, multi-targeted inhibitor for c-Met(WT/mutants) with IC50 of 0.4-2.5 nM, less potent to Ron, Flt1; 8- to 30-fold greater selectivity of c-Met targets versus FGFR1, FGFR2, FGFR3, PDGFRβ, KDR, Flt3, Flt4, TrkA, and TrkB.
M3396 NVP-BVU972 NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.
M2665 EMD 1214063 EMD 1214063 is a potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer.
M1922 MGCD265 MGCD265 is a novel multitargeted receptor tyrosine kinase (RTK) inhibitor that targets the mesenchymal epithelial transition (c-Met) and the vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2, and VEGFR3).
M1901 Golvatinib Golvatinib (E7050) is an orally bioavailable dual kinase inhibitor of c-Met and VEGFR-2 tyrosine kinases with potential antineoplastic activity.
M1899 PHA-665752 PHA-665752 is a selective small molecule c-MET inhibitor (Ki of 4 nM, IC50 of 9 nM).
M1890 SU11274 SU11274 is a selective c-Met inhibitor (IC50 = 0.01 μM in vitro).
M1811 Tivantinib (ARQ-197) Tivantinib (ARQ 197) is a selective and oral small-molecule inhibitor of c-Met with a minimal IC50 value of 0.1 μM.
M1793 JNJ-38877605 JNJ-38877605 is a small-molecule, ATP-competitive inhibitor of the catalytic activity of c-Met with an IC50 of 4 nM.
M1777 SGX523 SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo.
M1758 Foretinib Foretinib (XL880, GSK1363089) is a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2 (VEGFR2) with IC50 value of 0.4 nM for c-MET.
M1745 AMG-458 AMG-458 is a potent, selective and orally bioavailable c-Met inhibitor, with Ki values of 1.2 nM and 2.0 nM for human and mouse c-Met, respectively.
M1683 BMS 794833 BMS-794833 is a potent ATP competitive Met/VEGFR-2 kinase inhibitor.
M1682 BMS-777607 BMS-777607 is a selective and potent small-molecule met kinase inhibitor for c-Met, Axl, Ron and Tyro3 with IC50s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively.
M1647 AMG-208 AMG-208 is a potent small molecular inhibitor c-Met with an IC50 of 9.3 nM.
M54465 Caveolin-1 (82-101) amide (human, mouse, rat) Caveolin-1 (82-101) amide (human, mouse, rat) (Caveolin-1 scaffolding domain peptide) is a peptide that reverses aging-associated deleterious changes in multiple organs.
M50426 Norleual Norleual, an angiotensin (Ang) IV analog, is a hepatocyte growth factor (HGF)/c-Met inhibitor with an IC50 of 3 pM.
M50210 Fosgonimeton Fosgonimeton is a potentially first-in-class Hepatocyte Growth Factor Receptor (HGF) agonist that enhances HGF/MET signaling pathway activity for Alzheimer's Disease (AD) research.
M43491 SU 5616 SU 5616 is an organic compound.




Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.